Companies › Fresenius Kabi
1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SMOFlipid Lipid emulsion containing soybean oil, MCT, olive oil, and fish oil for parenteral nutriti | – | Phase 4 | Malnutrition, Child | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06049680 | SMOFlipid | Phase 4 | Malnutrition, Child | Metabolic and endocrine | Nov 2026 |
No annotated target.
–
Renibus Therapeutics Chendu DIAO Pharmaceutical Group Kowa Company Azafaros Waterstone Pharmaceutical (Wuhan)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.